10X Genomics
TXG
$70.11
+2.22%
10x Genomics is a life science technology company that develops instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution, spanning its Chromium, Visium, and Xenium platforms. The company occupies a leading position in the single-cell and spatial transcriptomics niche, competing with the broader life-science tools industry while differentiating through an integrated hardware-plus-consumables razor-and-blade model. The current investor narrative has shifted dramatically from a multi-year post-COVID destocking and biopharma-capex downturn toward a potential turnaround, with the stock up over 400% in the past year as revenue declines have moderated and gross margins have stabilized near 70%. Recent attention has centered on a patent litigation victory against Parse Biosciences, though the market's muted reaction to the $4.8M verdict underscores lingering skepticism about near-term monetization and legal cost overhangs.…
TXG
10X Genomics
$70.11
Related headlines
Investment Opinion: Should I buy TXG Today?
Rating: Hold. The core thesis is that 10x Genomics has stabilized its business with a fortress balance sheet, stable 70% gross margins, and positive free cash flow, but the stock has run far ahead of fundamentals, trading 24% above the analyst average target of $52.13. The consensus recommendation is "buy" with a mean of 2.39, yet the implied downside to the average target makes the risk/reward unattractive at current levels.
Supporting evidence: The trailing PS of 3.17x is well below the company's historical range of 6.91x to 48.04x, suggesting a relative discount on sales. However, the forward PS of 9.1x, based on consensus revenue of $879.78M, prices in a significant acceleration that has not appeared, with Q1 2026 revenue declining 2.61% year-over-year. Gross margin is healthy at 70.39%, and operating margin has improved to -11.30% from -25.39% a year ago, while TTM free cash flow of $122.18M and $490.29M in cash provide a solid financial foundation. The implied upside to the analyst high target of $70.00 is just 2.1%, while the downside to the low target of $40.00 is -41.7%, creating an unfavorable asymmetry.
Risks and conditions: The biggest risks are a failure to reaccelerate revenue growth, multiple compression toward the consensus target, and high volatility given the 2.077 beta. This Hold would upgrade to Buy if revenue growth turns positive and the stock pulls back toward the $52-$55 range, improving the risk/reward. It would downgrade to Sell if revenue declines accelerate or if the stock breaks below the $55 support zone, signaling a reversal of the momentum trade. Valuation verdict: the stock is overvalued relative to analyst targets and its own forward sales multiple, but fairly valued on a trailing PS basis relative to its history, creating a conflicted picture that supports a Hold rating.
Sign up to view all
TXG 12-Month Price Forecast
The forward-looking view is balanced but cautious. The company has clearly stabilized its financials with positive free cash flow, a fortress balance sheet, and stable gross margins, but revenue growth remains negative and the stock has priced in a recovery that has yet to materialize. The analyst consensus target of $52.13 implies significant downside, and the high target of $70.00 offers minimal upside, creating an unfavorable risk/reward at current levels. The extreme beta of 2.077 means the stock is likely to amplify any market downturn, and the recent muted reaction to the patent verdict suggests skepticism about near-term catalysts. I would upgrade to bullish if revenue growth turns positive for two consecutive quarters and the stock pulls back to the $52-$55 range, improving the margin of safety. I would downgrade to bearish if revenue declines accelerate or if the stock breaks below the $55 support zone, signaling a reversal of the momentum trade.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on 10X Genomics's 12-month outlook, with a consensus price target around $52.13 and implied upside of -25.6% versus the current price.
Average Target
$52.13
0 analysts
Implied Upside
-25.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $70
Analyst target range
The stock is covered by 15 analysts with a consensus recommendation of "buy" (recommendation mean of 2.39 on a scale where lower is more bullish), and an average price target of $52.13. Against the current price of $68.59, this implies a downside of approximately -24.0% to the consensus target, a striking disconnect that suggests the stock has run well ahead of where the sell-side believes fair value lies. The consensus leans bullish on rating but bearish on price, a classic setup where analysts like the story but cannot justify the valuation after a 425% one-year move. The target range spans $40.00 to $70.00, with the high target of $70.00 essentially matching the current price and the 52-week high of $69.67, implying that even the most optimistic analyst sees limited further upside. The low target of $40.00 prices in a scenario of continued revenue stagnation, margin pressure, and competitive share loss, representing roughly -42% downside from current levels. The spread between high and low is $30.00, or 75% of the low target, signaling high uncertainty and weak conviction among analysts. Institutional ratings show a predominantly neutral-to-constructive posture, with recent actions including Canaccord Genuity reiterating Buy (July 14), Morgan Stanley and Citigroup maintaining Equal Weight/Neutral (July 8-9), and Barclays reiterating Overweight (June 24), but notably no upgrades to Buy from the neutral camp despite the massive rally. The absence of recent upgrades alongside a price that exceeds the average target suggests analysts are waiting for fundamental confirmation, and the wide target dispersion combined with the negative implied return makes this a high-risk, high-volatility name where the technical momentum and fundamental valuation are in direct conflict.
Bulls vs Bears: TXG Investment Factors
The bull case rests on a fortress balance sheet, stable 70% gross margins, narrowing losses, and positive free cash flow, all of which suggest the turnaround is real. The bear case is equally compelling: revenue is still declining 2.61% year-over-year, the stock trades 24% above the analyst average target of $52.13, and the forward PS of 9.1x prices in an acceleration that has yet to appear. Currently, the bear evidence on valuation and growth is stronger, as the technical momentum has detached from fundamental performance. The single most important tension is whether consumables pull-through from the installed base can reaccelerate revenue growth before the valuation multiple compresses. If revenue growth turns positive in the next two quarters, the bull case gains credibility; if it remains negative, the stock is vulnerable to a sharp re-rating toward the consensus target.
Bullish
- Fortress balance sheet with $490M cash: Debt-to-equity is just 0.198 and the current ratio is 4.46, with $490.29M in cash against an $8.0B market cap. This gives TXG ample runway to fund operations and R&D without dilutive financing, a critical de-risking milestone after years of cash burn.
- Gross margin stable near 70%: Gross margin was 70.39% in Q1 2026, up from 68.09% in Q1 2025 and 67.24% in Q4 2024. This stability amid revenue pressure demonstrates pricing power and a favorable consumables mix, which is the foundation of the razor-and-blade model.
- Operating losses narrowing sharply: Operating margin improved to -11.30% in Q1 2026 from -25.39% in Q1 2025 and -30.20% in Q4 2024. Net loss shrank to -$13.47M from -$34.36M a year ago, showing meaningful cost discipline with R&D at $56.85M and SG&A at $66.38M.
- Positive free cash flow generation: TTM free cash flow is $122.18M, with Q1 2026 FCF of $24.52M on operating cash flow of $26.12M. Minimal capex of $1.60M means the company now funds operations internally, reducing financial risk.
Bearish
- Revenue still declining year-over-year: Q1 2026 revenue of $150.84M fell 2.61% versus Q1 2025's $154.88M, following a Q4 2025 print of $166.03M and Q3 2025's $149.00M. The multi-quarter trend shows stabilization, not growth, and the post-pandemic capital equipment reset continues to weigh on instrument sales.
- Stock trades 24% above analyst average target: The consensus average price target is $52.13 against the current price of $68.59, implying -24.0% downside. Even the highest analyst target of $70.00 is essentially at the current price and 52-week high of $69.67, suggesting limited further upside even in the bull case.
- Valuation stretched on forward sales: The forward PS implied by consensus revenue of $879.78M against the ~$8.02B market cap is about 9.1x, a premium to the trailing PS of 3.17x. This signals the market expects meaningful revenue acceleration that has not yet materialized, leaving little margin for execution disappointment.
- Negative earnings and weak profitability: Q1 2026 net income was -$13.47M with a net margin of -8.93%, and trailing EPS is -$0.021. The forward PE of 337.33x reflects near-zero expected earnings, making the stock expensive on any earnings-based metric.
TXG Technical Analysis
TXG is in a powerful, sustained uptrend, with the shares up 425.19% over the trailing year and 312.70% year-to-date, massively outperforming the S&P 500's 16.22% and 12.08% respective gains. At a current price of $68.59, the stock sits at approximately 98.4% of its 52-week range (low of $11.16, high of $69.67), meaning it is trading just below its absolute peak and signaling strong momentum but also elevated overextension risk. This positioning near the highs reflects a market that has aggressively repriced the turnaround story, leaving little margin for execution disappointment. Recent momentum remains firmly positive but is decelerating in rate-of-change terms: the 1-month gain of 18.77% and 3-month gain of 137.83% compare to the 6-month gain of 265.03%, indicating the sharpest acceleration occurred earlier in the year. The 1-month relative strength versus SPY of +19.83% confirms continued leadership, and the most recent session's +3.33% move on 1.83M shares shows buyers remain in control, though the slowing monthly cadence could signal a maturing advance rather than a reversal. Key technical support rests at the 52-week low of $11.16, with a more actionable near-term floor likely around the $55-$58 breakout zone from August; resistance is defined by the 52-week high of $69.67, and a clean breakout above that level would confirm trend continuation, while a breakdown below $55 would suggest the parabolic move is unwinding. The stock's beta of 2.077 means it is roughly 108% more volatile than the market, so a 10% SPY drawdown could translate to a 20%+ move in TXG, demanding disciplined position sizing. The maximum drawdown of -28.03% over the period further illustrates the severity of pullbacks this name can experience even within a broader uptrend.
Beta
2.08
2.08x market volatility
Max Drawdown
-28.0%
Largest decline past year
52-Week Range
$11-$70
Price range past year
Annual Return
+454.7%
Cumulative gain past year
| Period | TXG Return | S&P 500 |
|---|---|---|
| 1m | +25.0% | -2.0% |
| 3m | +120.8% | +1.4% |
| 6m | +304.1% | +15.0% |
| 1y | +454.7% | +15.7% |
| ytd | +321.8% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TXG Fundamental Analysis
Revenue has been essentially flat to slightly declining, with Q1 2026 revenue of $150.84M representing a -2.61% year-over-year decline versus Q1 2025's $154.88M, following a Q4 2025 print of $166.03M and Q3 2025's $149.00M. The multi-quarter trend shows stabilization rather than growth: the sequential progression from $149.00M to $166.03M to $150.84M reflects normal seasonality but no clear reacceleration, and the modest YoY decline implies the post-pandemic capital equipment reset is still weighing on instrument sales. Segment data shows consumables dominate at $129.80M (roughly 86% of product and service revenue of $149.90M), with instruments at just $11.26M and services at $8.83M, meaning the recovery thesis hinges almost entirely on consumable pull-through from the installed base rather than new instrument placements. Profitability remains elusive on a GAAP basis, with Q1 2026 net income of -$13.47M and a net margin of -8.93%, though this is a marked improvement from the -$34.36M loss in Q1 2025 and the -$49.03M loss in Q4 2024. Gross margin has been remarkably stable and healthy at 70.39% in Q1 2026, up from 68.09% in Q1 2025 and 67.24% in Q4 2024, indicating pricing power and a favorable consumables mix even amid revenue pressure. Operating margin remains negative at -11.30% in Q1 2026, but the trajectory from -25.39% in Q1 2025 and -30.20% in Q4 2024 shows meaningful cost discipline, with R&D at $56.85M and SG&A at $66.38M in the latest quarter. The balance sheet is a fortress: debt-to-equity is just 0.198, the current ratio is 4.46, and cash at the end of Q1 2026 stood at $490.29M against a market cap of roughly $8.0B. Free cash flow tells a compelling story, with TTM FCF of $122.18M and Q1 2026 FCF of $24.52M on operating cash flow of $26.12M, though capital expenditures are minimal at $1.60M. ROE of -5.47% and ROA of -5.05% remain negative but are improving, and the company's cash generation now comfortably funds operations without external financing, a critical de-risking milestone.
Quarterly Revenue
$150843000.0B
2026-03
Revenue YoY Growth
-2.6%
YoY Comparison
Gross Margin
70.4%
Latest Quarter
Free Cash Flow
$122180000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TXG Overvalued?
Because 10x Genomics reported negative trailing net income (EPS of -$0.021 and a trailing PE of -46.6), the PE ratio is not meaningful; the appropriate primary metric is the price-to-sales ratio, which stands at 3.17x on a trailing basis. The forward PE of 337.33x is technically positive but reflects near-zero expected earnings, making it a poor valuation anchor, while the EV/Sales of 13.25x and EV/EBITDA of 439.61x highlight how far the company is from normalized profitability. The gap between the trailing PS of 3.17x and the historical PS readings (which ranged from 6.91x to 48.04x over the past several years) suggests the market has already substantially de-rated the stock on a sales basis even as the share price has soared, because the market cap has been rebuilt on a much larger revenue base. Peer comparison is challenging given the sparse industry-average data, but the current PS of 3.17x is well below the company's own recent history and below typical high-growth life-science tools peers that often trade at 5-10x sales, implying a relative discount that may reflect the negative earnings and flat growth. The forward PS implied by consensus revenue of $879.78M against the current market cap of roughly $8.02B is about 9.1x, a premium to the trailing 3.17x that signals the market expects meaningful revenue acceleration that has not yet materialized. Historically, TXG's PS ratio has compressed dramatically from 116.13x in Q4 2021 to 3.17x today, a 97% de-rating that reflects both the revenue base quadrupling and the multiple collapsing as growth stalled. The current 3.17x PS sits near the bottom of the multi-year band, which could indicate a value opportunity if the turnaround gains traction, or a value trap if revenue growth fails to reaccelerate. The PEG ratio of 0.61 is below 1.0, which on its face suggests undervaluation relative to growth, but this metric is unreliable given the negative and near-zero earnings base.
PE
-46.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
439.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the company's continued GAAP losses and reliance on consumables. Q1 2026 net income was -$13.47M with a net margin of -8.93%, and trailing EPS is -$0.021, meaning profitability remains elusive. Revenue declined 2.61% year-over-year to $150.84M, and with consumables at 86% of product revenue, the recovery hinges almost entirely on pull-through from the installed base rather than new instrument placements. While free cash flow is positive at $122.18M TTM, any slowdown in consumable reorders or pricing pressure could quickly erode this cushion. The balance sheet is strong with $490.29M cash and debt-to-equity of 0.198, but the company must still bridge the gap to sustainable GAAP profitability.
Market and competitive risks are elevated by the stock's extreme valuation and momentum. The shares trade at a trailing PS of 3.17x but a forward PS of 9.1x, implying the market expects revenue acceleration that has not materialized. The consensus analyst target of $52.13 implies -24.0% downside, and even the high target of $70.00 offers minimal upside from $68.59. With a beta of 2.077, TXG is roughly 108% more volatile than the market, so a 10% SPY drawdown could translate to a 20%+ decline. The recent patent verdict win against Parse Biosciences generated only a $4.8M award and the stock fell 5% on the news, underscoring skepticism about near-term monetization and lingering legal cost overhangs. Competitive disruption in spatial transcriptomics and single-cell analysis could pressure pricing and market share.
Worst-case scenario: a continued revenue decline, failure to achieve GAAP profitability, and multiple compression as the market reprices the stock toward the analyst average target. If revenue growth remains negative and the forward PS compresses toward the trailing 3.17x, the stock could fall to the consensus target of $52.13, representing -24% from the current price. A more severe scenario, such as a recession or competitive share loss, could drive the stock toward the analyst low target of $40.00, a -42% decline, or even the 52-week low of $11.16 in a catastrophic outcome. Given the max drawdown of -28.03% over the past period, investors should be prepared for significant volatility and potential losses of 25-40% from current levels in an adverse scenario.
FAQ
The most severe risk is valuation compression: the stock trades 24% above the analyst average target of $52.13, and a re-rating toward that level would mean a -24% loss. Financial risk is also significant, with Q1 2026 net income of -$13.47M and a net margin of -8.93%, meaning the company remains unprofitable on a GAAP basis. Competitive risk is high in the single-cell and spatial transcriptomics market, where new entrants could pressure pricing and market share. Macro risk is amplified by the stock's beta of 2.077, meaning a 10% market decline could translate to a 20%+ drop in TXG. Additionally, the recent patent verdict win against Parse Biosciences generated only a $4.8M award and the stock fell 5%, highlighting skepticism about near-term monetization and legal cost overhangs. Ranked by severity: valuation compression, followed by revenue stagnation, competitive disruption, and macro sensitivity.
The 12-month forecast is divided into three scenarios. The base case (50% probability) targets $52-$65, assuming revenue stabilizes and the stock consolidates around the analyst average target of $52.13. The bull case (25% probability) targets $70-$85, driven by revenue growth turning positive and operating margins approaching breakeven. The bear case (25% probability) targets $40-$52, assuming revenue declines accelerate and the stock re-rates toward the analyst low target of $40.00. The most likely scenario is the base case, with the key assumption that revenue growth remains flat to slightly negative and gross margins hold near 70%. The wide target range reflects high uncertainty, and the stock's high beta means outcomes can deviate significantly from these targets.
TXG's valuation is conflicted. On a trailing price-to-sales basis, the stock trades at 3.17x, which is well below its historical range of 6.91x to 48.04x, suggesting a relative discount. However, the forward PS of 9.1x, based on consensus revenue of $879.78M, is a premium to the trailing multiple and implies the market expects significant revenue acceleration that has not materialized. The forward PE of 337.33x and EV/EBITDA of 439.61x reflect near-zero profitability, making earnings-based metrics meaningless. Compared to high-growth life-science tools peers that often trade at 5-10x sales, TXG's trailing PS is low, but the negative earnings and flat growth justify a discount. The market is paying a premium for a turnaround that is not yet confirmed in the financials, and the analyst average target of $52.13 suggests the stock is overvalued relative to sell-side expectations.
At the current price of $68.59, TXG presents an unfavorable risk/reward for most investors. The stock trades 24% above the analyst average target of $52.13, and even the highest target of $70.00 offers only 2.1% upside. While the company has a fortress balance sheet with $490.29M in cash and positive free cash flow of $122.18M TTM, revenue is still declining 2.61% year-over-year. The biggest downside risk is a re-rating toward the consensus target, implying -24% downside, or toward the low target of $40.00, implying -42% downside. For risk-tolerant investors, a pullback to the $52-$55 range would improve the risk/reward and could make the stock a good buy if revenue growth turns positive. However, at current levels, the stock is overextended and better suited for traders than long-term investors.
TXG is more suitable for short-term trading than long-term holding at current levels, given the extreme volatility and overextension. The stock has a beta of 2.077, no dividend, and a max drawdown of -28.03% over the past period, making it unsuitable for income or conservative investors. The company is in a turnaround phase with negative GAAP earnings and declining revenue, so earnings visibility is low. For long-term investors, a better entry point would be after a pullback to the $52-$55 range and evidence of revenue reacceleration. A suggested minimum holding period for a long-term position would be 2-3 years to allow the turnaround to fully play out. Short-term traders can capitalize on momentum, but must use tight stop-losses given the potential for sharp reversals.